Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimethyl Fumarate with Temozolomide and Radiation in Glioblastoma
NCT02337426Phase 1Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Feb 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dimethyl fumarate in glioblastoma multiforme (GBM), sponsored by Virginia Commonwealth University. Primary endpoint: Recommended Phase 2 Dose up to 6 weeks. Started Feb 2015; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02337426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337426.